Work

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.9032

Authors: Nikhil Shukla, Sandra K. Althouse, Ahad Ali Sadiq, Shadia Ibrahim Jalal, Salma K. Jabbour, Robin Zon, Goetz H. Kloecker, William B. Fisher, Karen L. Reckamp, Ebenezer A. Kio, Robert M. Langdon, Bamidele Adesunloye, Ryan D. Gentzler, Nasser H. Hanna, Greg Andrew Durm

Institutions: Indiana University Indianapolis, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Rutgers Cancer Institute, University of Louisville, Cedars-Sinai Medical Center, Goshen Health, Nebraska Cancer Specialists, National Institutes of Health, University of Virginia Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030700861

Cites:

Cited by:

Related to: 10